AU2016284866B2 - Multispecific antigen binding proteins - Google Patents

Multispecific antigen binding proteins Download PDF

Info

Publication number
AU2016284866B2
AU2016284866B2 AU2016284866A AU2016284866A AU2016284866B2 AU 2016284866 B2 AU2016284866 B2 AU 2016284866B2 AU 2016284866 A AU2016284866 A AU 2016284866A AU 2016284866 A AU2016284866 A AU 2016284866A AU 2016284866 B2 AU2016284866 B2 AU 2016284866B2
Authority
AU
Australia
Prior art keywords
domain
polypeptide
protein
antigen
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016284866A
Other languages
English (en)
Other versions
AU2016284866A1 (en
Inventor
Laurent Gauthier
Benjamin Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2015/064070 external-priority patent/WO2015197598A2/en
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of AU2016284866A1 publication Critical patent/AU2016284866A1/en
Application granted granted Critical
Publication of AU2016284866B2 publication Critical patent/AU2016284866B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016284866A 2015-06-23 2016-06-23 Multispecific antigen binding proteins Active AU2016284866B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2015/064070 WO2015197598A2 (en) 2014-06-27 2015-06-23 Multispecific antigen binding proteins
AUPCT/EP2015/064070 2015-06-23
US201562271491P 2015-12-28 2015-12-28
US62/271,491 2015-12-28
PCT/EP2016/064528 WO2016207273A2 (en) 2015-06-23 2016-06-23 Multispecific antigen binding proteins

Publications (2)

Publication Number Publication Date
AU2016284866A1 AU2016284866A1 (en) 2018-02-15
AU2016284866B2 true AU2016284866B2 (en) 2022-09-29

Family

ID=57584754

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016284866A Active AU2016284866B2 (en) 2015-06-23 2016-06-23 Multispecific antigen binding proteins

Country Status (7)

Country Link
US (1) US20200048345A1 (enExample)
EP (1) EP3313876B1 (enExample)
JP (1) JP6840682B2 (enExample)
AU (1) AU2016284866B2 (enExample)
CA (1) CA2990511A1 (enExample)
DK (1) DK3313876T3 (enExample)
WO (1) WO2016207273A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015197593A1 (en) 2014-06-27 2015-12-30 Innate Pharma MULTISPECIFIC NKp46 BINDING PROTEINS
DK3160994T3 (da) 2014-06-27 2025-05-05 Innate Pharma Multispecifikke antigenbindende proteiner
WO2016207278A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
CN107850596B (zh) 2015-07-24 2020-12-04 先天制药公司 用于检测组织浸润nk细胞的方法
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
SG11201907271PA (en) * 2017-02-10 2019-09-27 Dragonfly Therapeutics Inc Proteins binding psma, nkg2d and cd16
JP2020510646A (ja) * 2017-02-20 2020-04-09 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
CA3054081A1 (en) * 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding gd2, nkg2d and cd16
KR20240060739A (ko) * 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
KR20190123299A (ko) * 2017-02-27 2019-10-31 드래곤플라이 쎄라퓨틱스, 인크. Caix, ano1, 메소텔린, trop2, cea, 또는 클라우딘-18.2를 표적화하는 다중특이적 결합 단백질
WO2018217947A1 (en) * 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
JP2020521448A (ja) * 2017-05-23 2020-07-27 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、およびｒｏｒ１またはｒｏｒ２に結合するタンパク質
KR20200010429A (ko) * 2017-05-23 2020-01-30 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
JP6951545B2 (ja) * 2017-07-21 2021-10-20 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． 単鎖ｖｈ及び重鎖抗体
MX2020002036A (es) * 2017-08-23 2020-03-24 Dragonfly Therapeutics Inc Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
AU2018371114A1 (en) * 2017-11-21 2020-05-07 Innate Pharma Multispecific antigen binding proteins
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
SG11202007579TA (en) * 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
WO2019217332A1 (en) * 2018-05-07 2019-11-14 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
MX2020012273A (es) * 2018-05-16 2021-04-28 Dragonfly Therapeutics Inc Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
WO2019226617A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EP3833385A4 (en) * 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
CN116368154A (zh) * 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
JP2024511465A (ja) 2021-03-26 2024-03-13 イナート・ファルマ・ソシエテ・アノニム Ｎｋ細胞エンゲージングのためにサイトカインに融合したｎｋｐ４６結合性部位、がん抗原結合性部位を含む多特異性タンパク質
WO2022258678A1 (en) * 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
MX2023014647A (es) * 2021-06-09 2024-01-31 Innate Pharma Proteinas de union a nkp46 multiespecificas.
CN113838523A (zh) * 2021-09-17 2021-12-24 深圳太力生物技术有限责任公司 一种抗体蛋白cdr区域氨基酸序列预测方法及系统
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物
EP4587123A1 (en) * 2022-09-15 2025-07-23 Avidicure IP B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000086A2 (en) * 2003-06-30 2005-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
WO2011133886A2 (en) * 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
WO2012088302A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU7266698A (en) 1997-04-30 1998-11-24 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
DE20308171U1 (de) 2003-05-21 2003-07-31 Aesculap AG & Co. KG, 78532 Tuttlingen Wirbelkörperersatzimplantat
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
SG173322A1 (en) 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
BRPI1014089A2 (pt) * 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
SI2506871T1 (sl) * 2009-11-30 2016-12-30 Janssen Biotech, Inc. Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2881765C (en) 2012-09-19 2024-02-13 Innate Pharma Kir3dl2 binding agents
US20140377269A1 (en) * 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
WO2015197593A1 (en) * 2014-06-27 2015-12-30 Innate Pharma MULTISPECIFIC NKp46 BINDING PROTEINS
WO2016207278A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
AU2021414400A1 (en) * 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000086A2 (en) * 2003-06-30 2005-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
WO2011133886A2 (en) * 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
WO2012088302A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. ROZAN ET AL: MOLECULAR CANCER THERAPEUTICS, vol. 12, no. 8, 1 August 2013 (2013-08-01), pages 1481 - 1491 *
KUFER P ET AL, "A revival of bispecific antibodies", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (2004-05-01), vol. 22, no. 5, doi:10.1016/J.TIBTECH.2004.03.006, ISSN 0167-7799, pages 238 - 244 *
MULLER K M ET AL, "The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (1998-01-30), vol. 422, no. 2, pages 259 - 264 *
Roland Kontermann; "Dual targeting strategies with bispecific antibodies", mAbs (2012), Volume 4 Issue 2, pp: 182-197 *
SHAN CHUNG ET AL, "Quantitative evaluation of fucose reducing effects in a humanized antibody on Fc[gamma] receptor binding and antibody-dependent cell-mediated cytotoxicity activities", MABS, US, (2012-05-01), vol. 4, no. 3 *

Also Published As

Publication number Publication date
WO2016207273A2 (en) 2016-12-29
US20200048345A1 (en) 2020-02-13
WO2016207273A3 (en) 2017-02-16
CA2990511A1 (en) 2016-12-29
JP2018519296A (ja) 2018-07-19
JP6840682B2 (ja) 2021-03-10
EP3313876B1 (en) 2025-01-22
AU2016284866A1 (en) 2018-02-15
EP3313876A2 (en) 2018-05-02
DK3313876T3 (da) 2025-04-22

Similar Documents

Publication Publication Date Title
AU2021200972B2 (en) MULTISPECIFIC NKp46 BINDING PROTEINS
US20250215107A1 (en) Multispecific nk engager protein
AU2015279321B2 (en) Multispecific antigen binding proteins
EP3313876B1 (en) Multispecific antigen binding proteins
AU2016383475A1 (en) Variable regions for NKp46 binding proteins
US20200325232A1 (en) Multispecific antigen binding proteins
US20190322767A1 (en) Heterodimeric antigen binding proteins
CA2990518C (en) Multispecific nk engager proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)